Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effects of Sumac (Rhus Coriaria L.) Powder Supplementation in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial Publisher Pubmed



Kazemi S1 ; Shidfar F1 ; Ehsani S1 ; Adibi P2 ; Janani L3 ; Eslami O1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

Source: Complementary Therapies in Clinical Practice Published:2020


Abstract

Background: In recent years, great attention has been paid to the role of herbal medicine in the management of non-alcoholic fatty liver disease (NAFLD). Sumac (Rhus coriaria L.) is a popular herb which contains major bioactive compounds known for a variety of health benefits. This study aimed to assess the effects of sumac powder supplementation on hepatic fibrosis and some metabolic markers in patients with NAFLD. Methods: Eighty-four patients diagnosed with NAFLD were included in this randomized double-blind placebo-controlled clinical trial. They were randomly assigned to receive 2000 mg per day sumac powder (n = 42) or placebo (n = 42) for 12 weeks. Also, both groups received a 500-calories deficit diet plan. Hepatic fibrosis and liver enzymes (ALT and AST) as well as fasting blood sugar (FBS), serum insulin, HbA1c, HOMA-IR (insulin resistance index), QUICKI (insulin sensitivity index), malondialdehyde (MDA), and high sensitivity C-reactive protein (hs-CRP) were measured at baseline and the end of trial. Results: Eighty patients completed the trial. After 12-weeks of intervention, subjects in the sumac group showed a greater decrease in hepatic fibrosis and liver enzymes as well as FBS, serum insulin, HbA1c, HOMA-IR, MDA, and hs-CRP, compared to the placebo (P-value < 0.05); while the QUICKI was significantly higher in the sumac group at the end of intervention. Conclusion: Daily intake of 2000 mg sumac powder along with a low-calorie diet for 12 weeks was beneficial for the management of NAFLD. © 2020 Elsevier Ltd
Experts (# of related papers)
Other Related Docs